[HTML][HTML] Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
BA Chan, BGM Hughes - Translational lung cancer research, 2015 - ncbi.nlm.nih.gov
In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …
[HTML][HTML] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer …
ACZ Gelatti, A Drilon, FC Santini - Lung cancer, 2019 - Elsevier
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of …
NI Lindeman, PT Cagle, DL Aisner… - … of pathology & …, 2018 - meridian.allenpress.com
Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …
Pathologists, the International Association for the Study of Lung Cancer, and the Association …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd, L Bazhenova… - The lancet …, 2016 - thelancet.com
Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA study phase II extension component
JCH Yang, MJ Ahn, DW Kim… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing (EGFR m) and T790M …
kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing (EGFR m) and T790M …
Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with …
JE Gray, I Okamoto, V Sriuranpong, J Vansteenkiste… - Clinical cancer …, 2019 - AACR
Purpose: To assess the utility of the cobas EGFR Mutation Test, with tissue and plasma, for
first-line osimertinib therapy for patients with EGFR-mutated (EGFR m; Ex19del and/or …
first-line osimertinib therapy for patients with EGFR-mutated (EGFR m; Ex19del and/or …
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
JL Kuiper, DAM Heideman, E Thunnissen, MA Paul… - Lung cancer, 2014 - Elsevier
Aim Non-small cell lung cancer (NSCLC)-patients with an epidermal growth factor receptor
(EGFR)-mutation have median progression-free survival (PFS) of 12 months on tyrosine …
(EGFR)-mutation have median progression-free survival (PFS) of 12 months on tyrosine …
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)
C Chouaid, C Dujon, P Do, I Monnet, A Madroszyk… - Lung cancer, 2014 - Elsevier
Objectives When advanced non-small-cell lung cancer (NSCLC) progresses during first-line
treatment, re-biopsy may be indicated to detect a possible new biological profile …
treatment, re-biopsy may be indicated to detect a possible new biological profile …
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical …
D Planchard, KH Brown, DW Kim, SW Kim… - Cancer Chemotherapy …, 2016 - Springer
Abstract Purpose Osimertinib (AZD9291) 80 mg once daily is approved by the US FDA for
the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has …
the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has …
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
T Singh, MF Hassanabad, AF Hassanabad - Biochimica et Biophysica Acta …, 2021 - Elsevier
Non-small cell lung cancer (NSCLC) represents the most common and fatal type of primary
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic …
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic …